IMPORTANCE Molecular aberrations in the phosphatidylinositol-3-kinase (PI3K) pathway drive tumorigenesis. Frequently co-occurring alterations in hormone receptors and/or human epidermal growth factor receptor 2 (HER2) may be relevant to mechanisms of response and resistance.
phatidylinositol 3,4,5-triphosphate, a lipid second messenger, and further activation of downstream effectors such as protein kinase B (AKT) and mammalian target of rapamycin (mTOR). 3 Phosphatase and tensin homologue (PTEN) dephosphorylates proteins in this pathway. 3 The PI3K pathway can be constitutively activated by genomic aberrations in cancer. 4 Common alterations include (1) activating mutations or/and amplification of the catalytic subunit alpha (PIK3CA), 5, 6 (2) loss of PTEN, 7 and (3) mutation and/or amplification of AKT, a serine/threonine-specific protein kinase. 8 These alterations are sufficient to induce tumorigenesis in preclinical models. [9] [10] [11] Genomic alterations of the PI3K pathway have been observed in diverse solid tumors, including, but not limited to, breast, endometrial, epithelial ovarian, prostate, bladder, colorectal, gastric, and pancreatic cancer, as well as various squamous cell cancers, melanoma, and glioblastoma. [12] [13] [14] However, these studies generally had small sample sizes, and it is difficult to capture the true frequency of alterations owing to the different techniques used in each study. The Cancer Genome Atlas has provided the most comprehensive evaluation to date, including an analysis of 12 major cancers and several studies in individual cancers. [15] [16] [17] Importantly, the PI3K/AKT/mTOR machinery often does not act alone. For instance, PIK3CA mutations induce resistance to anti-HER2 (human epidermal growth factor receptor 2) treatments.
18 PIK3CA mutations have also been correlated with hormone-receptor positivity in breast cancer, and the combination of the mTOR inhibitor everolimus with hormone modulators have shown clinical efficacy in breast and other cancers, though responses were not clearly associated with mutation status in some studies.
19-21
In the present study, we profile a large number of diverse solid tumors in a single laboratory certified by the Clinical Laboratory Improvement Amendment (CLIA). We catalogue the genomic abnormalities in several key members of the PI3K pathway as well as coexisting anomalies, including those in hormone and HER2 receptors.
Methods

Tissue Samples
Consecutive cases submitted to a commercial CLIA-certified laboratory (Caris Life Sciences) from January 2013 through December 2014 were analyzed. The tissue diagnoses were submitted based on pathologic assessment of physicians who requested the assays and were further verified by a pathologist at the Caris laboratory. Formalin-fixed paraffin-embedded tissues were processed as previously described. 22 In accordance with Western Institutional Review Board guidelines, patient identity protection was maintained throughout the study, so the study was considered exempt, and institutional review board approval was waived. Samples were sent from thousands of clinicians and institutions in 60 countries.
Next-Generation Sequencing
Next generation sequencing (NGS) analysis was performed on genomic DNA isolated from formalin-fixed paraffinembedded tissue using the MiSeq platform (Illumina). An Agilent custom-designed SureSelect XT assay was used to enrich a targeted NGS hotspot panel (47 genes). All variants reported by this assay were detected with greater than 99% confidence, based on the frequency of the mutation present and the amplicon coverage. The average depth of coverage for this assay is 1000×. Using the COSMIC database (Catalogue of Somatic Mutations in Cancer; http://cancer.sanger.ac.uk /cosmic), we did not report mutations if the alteration was considered benign. Known pathogenic variants, presumed pathogenic variants, and variants of unknown significance were included in the analysis. This test was not designed to distinguish between germline inheritance of a variant or acquired somatic mutation; it has the sensitivity to detect approximately a 10% population of cells containing a mutation.
Immunohistochemical Analysis
Immunohistochemical analysis (IHC) was performed on the tumor samples using commercially available detection kits and autostainers (Benchmark XT, Ventana Medical Systems Inc, and Autostainer Link 48, Dako). Primary antibodies used for protein detection were human epidermal growth factor receptor 2 (HER2) (clone 4B5, Ventana), PTEN (clone 6H2.1, Dako), estrogen receptor (ER) (clone SP1, Ventana), progesterone receptor (PR) (clone 1E2, Ventana), and androgen receptor (AR) (clone AR27, Leica Biosystems). The thresholds used to define positivity are described in eTable 1 in the Supplement. 
In Situ Hybridization
Either fluorescence in situ hybridization (FISH) or chromogenic in situ hybridization (CISH) was performed to detect copy number changes in ERBB2/HER2 (formerly HER2 or HER2/ neu). FISH was performed using the Pathvysion HER2 DNA Probe Kit (Abbott Laboratories). Interphase nuclei were examined. The signal of ERBB2/HER2 was compared with chromosome 17 centromere signals (CEP17), and a HER2/CEP17 ratio higher than 2.2 was considered amplified. CISH was performed using the INFORM HER2 Dual ISH DNA Probe Cocktail (Ventana) according to the manufacture's protocol. A HER2/ CEP17 ratio higher than 2.0 was considered amplified.
Statistical Analysis
A Fisher exact test with a 2-tailed P value was used to compare biomarker differences across histologic subtypes, using GraphPad software, version 6.00 (August 2012).
Results
Alterations in the PI3K pathway were common across cancers. Indeed, of 19 784 tumors analyzed, 13% had PIK3CA mutations; 30%, PTEN loss; 6%, PTEN mutations; and 1%, AKT1 mutations ( Table 1) . Thirty-eight percent of patients had an aberration in 1 or more of these genes and/or gene products 
PIK3CA Mutations
PIK3CA mutations were observed in 0% to 37% of solid tumors ( Figure 1 , Table 1 ; eTable 2 in the Supplement). The most commonly found mutated cancers were endometrial (37% of patients), breast (31%), cervical (29%), anal (27%), and bladder cancer (22%). Other cancers with identified mutations in more than 10% of cases included colorectal (17%), sarcomatoid renal cell carcinoma (15%), head and neck squamous cell carcinoma (14%), cancers of unknown primary (10%), salivary gland (10%), and nonmelanoma skin cancer (10%).
PTEN Loss and PTEN Mutations
The loss of PTEN was common, ranging from 57% in hepatocellular carcinoma to 2% in gastrointestinal stromal tumor ( Figure 1 , Table 1 ; eTable 2 in the Supplement). Frequent loss was also observed in ampullary adenocarcinoma (53%), prostate cancer (52%), germ cell tumors (50%), endometrial carcinoma (49%), colorectal cancer (48%), small intestinal cancer (40%), clear cell renal cell carcinoma (44%), extrahepatic cholangiocarcinoma (37%), esophageal and/or gastroesophageal junction cancer (35%), gastric cancer (36%), pancreatic cancer (32%), breast cancer (34%), and bladder cancer (31%). Loss of PTEN was less frequent in thymic carcinoma (9%), neuroendocrine tumors (7%), central nervous system tumors (6%), uveal melanoma (4%), and gastrointestinal stromal tumor (2%). PTEN mutation was less frequent than PTEN loss, affecting 0% to 14% of patients, except for endometrial cancer, in which 33% of individuals had PTEN mutations.
AKT1 Mutations
AKT1 mutations were infrequent, ranging from 0% to 4% of cases. Adenoid cystic carcinoma and thyroid carcinoma (4% of patients) were the most commonly mutated cancers, followed by adrenocortical (3%), breast (3%), and endometrial cancer (3%). Amplification of AKT1 was not evaluated.
PI3K/AKT/mTOR Combined Genomic Alterations
Aberrations of the PI3K/AKT/mTOR pathway were observed in 38% of solid tumors. As noted with PIK3CA mutations alone, epithelial cancers such as endometrial cancer, breast cancer, and gastrointestinal tract cancer were most commonly associated with genomic alterations in all the evaluated PI3K pathway biomarkers. Nonepithelial tumors such as melanoma, sarcoma, and neuroendocrine tumors harbored PI3K pathway alterations less often.
Mutation Hot Spots
PIK3CA mutations were observed most frequently in exon 9 (43.2%) and exon 20 (33.0%) (eFigure 1 in the Supplement). Specifically, E545K substitution in exon 9 accounted for 20.5%, and H1047R in exon 20 accounted for 20.6% of mutations in analyzed samples. Position 545 is within the helical domain and interacts with the N-terminal SH2 domain of the p85 regulatory subunit. 23 The change from glutamic acid (E) to lysine (K) causes charge reversal and disrupts the inhibitory interaction with p85. 5 The mutation of E545K was sufficient to induce tumorigenesis in a transgenic mouse model.
24,25
Position 1047 resides in the kinase domain and is located near the C-terminal end of the activation loop. 23 Substitution of histidine (H) to arginine (R) in this position likely changes the conformation of the activation loop 23 and results in the activation of the PI3K pathway. 25 The mutation of H1047R was sufficient to induce tumors in an animal model 26 and may be associated with favorable responses to PI3K/AKT/mTOR pathway inhibitors.
27
The most common PTEN mutation hot spot was a K267 frameshift mutation (6.6%) in exon 7. Position K267 resides in the calcium-binding region 3 (CRB3) loop of the C2 domain. 28 The mutation of K267 is sufficient to block PTEN membrane localization. 28 Coexistence of PTEN Mutation, PTEN Loss, PIK3CA Mutation, and AKT1 Mutation Loss of PTEN protein expression was the most common aberration (30% of patients), followed by PIK3CA mutation, and PTEN mutation (Table 1, Figure 1 and Figure 2 ). AKT1 mutation is a relatively rare event (only 1% of patients). PTEN mutation frequently occurs with PTEN loss.
Loss of PTEN expression is, however, not always associated with PTEN mutation. Only 13% of patients with PTEN loss had a PTEN mutation (675 of 5005); on the other hand, 72.5% of patients with PTEN mutation had PTEN loss (675 of 931) (Figure 2 ). Fourteen percent of patients (700 of 5005) with PTEN loss also had a PIK3CA mutation; 32% of patients (296 of 931) with a PTEN mutation also had a PIK3CA mutation; and 14% of patients (296 of 2156) with PIK3CA mutations also had PTEN mutations.
Association With Hormone-Receptor Pathways
It is well recognized that the PI3K/AKT/mTOR pathway interacts with other signaling pathways. Our IHC studies of key signaling pathways revealed increased expression of the AR, ER, and PR in PIK3CA-mutated samples compared with PIK3CA wild-type samples ( Table 2) . Androgen receptor was overexpressed in 29% of PIK3CA-mutated cases, whereas overexpression of AR was seen in only 16% of PIK3CA wild-type samples (P < .001). Similarly, ER and PR were expressed more commonly in PIK3CA-mutated cases than in PIK3CA wildtype cases (ER, 44% of PIK3CA-mutant cases overexpressed ER, whereas only 23% of PIK3CA wild-type cases overexpressed ER [P < .001]; PR, 33% vs 13% [P < .001]) ( Table 3) . Conversely, in ER-positive patients, PIK3CA was mutated in 23% of cases, while in ER-negative patients, PIK3CA was mutated in only 11% of cases (P < .001) ( Figure 3A) . These results indicate a strong interaction between the PI3K/AKT/mTOR pathway and the hormone-receptor pathways.
Coalterations With HER2
In this study, patients with overexpressed or amplified HER2 also more frequently had PIK3CA mutations than did HER2-normal patients (22% vs 13%; P < .001) ( Figure 3B ). HER2 overexpression or amplification is associated with decreased frequency of PTEN loss (27% vs 30% when HER2 status is normal, P < .001. Figure 3B ). Additional analysis of the HER2-positive PIK3CA-or PTEN-mutated cases was performed to assess differences in expression of ER and identi- 
Discussion
To our knowledge, this is the largest study ever to provide the frequency of genomic and proteomic alterations in a variety of PI3K/AKT/mTOR-relevant pathways. The analysis was performed at a CLIA-certified laboratory with consistency in techniques and platforms. The large number of samples is likely sufficient to capture the true frequency of these alterations, and provide a reference guide for deployment of targeted therapies.
Conclusions from many previous studies have been limited owing to small sample sizes and the different methods used to measure alterations. For example, the published frequency of PTEN loss in prostate cancer varies from 13% to 65%. [29] [30] [31] [32] [33] [34] These discrepant frequencies could be explained by several factors: (1) small number of specimens (range, 22-80); (2) differences in disease stage of the specimens; and (3) the distinct techniques that were used in these studies. In addition, cutoff points for designating PTEN loss may vary. We defined PTEN loss as no protein expression in more than 50% of cells by IHC. Some studies may have a more strict defini- Venn diagram showcases the co-incidence of PTEN mutations, PIK3CA mutations, and PTEN loss. The number represents sample numbers, in which all 3 biomarkers were evaluated from a total of 17 546 cases. For example, of 5005 cases with phosphatase and tensin homologue (PTEN) loss, 3859 had neither PTEN mutations nor PIK3CA mutations, while 675 cases had a PTEN mutation (446 with only a PTEN mutation, and 229 with both a PTEN mutation and a PIK3CA mutation). Therefore, only 13% of patients with PTEN loss had a PTEN mutation (675 of 5005); on the other hand, 72.5% of patients with PTEN mutation had PTEN loss (675 of 931). Another 471 cases with PTEN loss had only a PIK3CA mutation. (Owing to low incidence, AKT1 is not shown in the Venn diagram.) a All evaluations performed by next-generation sequencing mutation analysis, and data reported as frequency percentages.
b Differences between wild-type and mutated PIK3CA and PTEN genes was not significant; in all other cases they were (P<.001). tion, and therefore the incidence of PTEN loss may be lower in those studies. Specific to molecular alterations, large-scale data are available from The Cancer Genome Atlas (TCGA) (http: //cancergenome.nih.gov/), and an analysis using these data was performed by Kandoth et al. 16 Overall, PIK3CA was mutated in 13% of our patients vs about 18% of the TCGA patients; PTEN was mutated in about 6% in the present study vs approximately 10% in the TCGA; and in both data sets, AKT mutation rates were about 1% (eTable 3 in the Supplement). 16 Differences in overall rates of mutations could be due to several factors including, but not limited to, the large numbers of diverse cancers (including rare tumors) assessed in our data set (>40 types of cancer vs the 12 cancer types assessed by Kandoth and colleagues), and the difference in patient numbers (19 784 vs 3281 patients). 16 Loss of PTEN identified by IHC was seen in about 30% of our patients and was not assessed in TCGA.
Compared with the TCGA pan-cancer analysis, our study demonstrated similar mutation rates in cancers such as breast, colorectal, bladder, lung, and renal cell carcinoma. Recently, the PI3K pathway has been conjectured to be important in the clinic, and agents targeting the PI3K/AKT/ mTOR machinery have entered the clinical arena. 35 In breast cancer, treatment with everolimus, an mTOR inhibitor, and exemestane (hormone modulator) demonstrated prolonged overall survival in hormone receptor-positive metastatic breast cancer and was approved by the US Food and Drug Administration (FDA). 20 Everolimus is also approved by the FDA for renal cell carcinoma, pancreatic neuroendocrine tumor, and subependymal giant cell astrocytoma. [36] [37] [38] In hematologic cancers, idelalisib, a PI3K delta inhibitor, is approved by the FDA for chronic lymphocytic leukemia, small lymphocytic lymphoma, and follicular lymphoma. 39 Interestingly, aspirin use in patients with colorectal cancer who harbor PIK3CA mutations was associated with superior survival in an observational study, perhaps by inhibiting of cyclooxygenase-2, which is potentiated by PI3K mutations. 40 Targeting the PI3K pathway is currently being investigated in multiple tumor types. were more frequently discerned in patients with higher expression of ER, PR, and AR. Interestingly, PTEN loss was inversely correlated with ER and AR expression (though PTEN loss was still found in both ER-positive and ER-negative tumors as well as AR-positive and AR-negative cancers; Figure 3A and Table 2 ). In general, KRAS and EGFR mutations are mutually exclusive. 68 In our analysis, mutation of PIK3CA was associated with higher frequency of KRAS mutations. Also, mutations of PIK3CA were associated with increased levels of HER2 and other markers such as DNA topoisomerase 2-alpha (TOP2A) ( Tables 2 and 3 ). TOP2A possibly predicts vulnerability to anthracyclines and etoposide, setting the stage for rational combinations. These results imply that alterations of the PI3K machinery are not exclusive of other key signaling pathways but rather are associated with a high chance of crosstalk with other pathways. A similar observation was reported in a study of lung cancer. 64 When making treatment decisions based on molecular profile, multiple alterations should be considered prior to determining therapy.
Conclusions
In conclusion, this large, single laboratory study helps solidify the frequency of PI3K pathway aberrations across tumor types and the coexisting patterns of alterations in a variety of other markers, including hormone receptors and HER2. The data presented here can be used to help design clinical studies that appropriately investigate and treat tumors with targeted agents.
